M. Daniels et al., PHASE-II TRIAL OF UFT ACTIVITY IN PRETREATED BREAST-CANCER PATIENTS, Japanese Journal of Clinical Oncology, 23(6), 1993, pp. 363-365
Seventy metastatic breast adenocarcinoma patients, pretreated with sta
ndard hormonotherapy or chemotherapy, received continuous UFT at 10 mg
/kg/day, orally, for at least two months. There were one complete resp
onse (1.5%), 12 partial responses (17%), one minor response and 37 dis
ease stabilizations. The median duration of response was nine months.
A greater efficacy was demonstrated in 29 patients with soft tissue di
sease, with a rate of 38% objective responses. The major toxicity was
gastrointestinal, with 45% of patients developing nausea and vomiting
and 30%, diarrhea. Bone marrow toxicity was slight. UFT has shown anti
tumor activity in our group of pretreated patients, especially these w
ith the cutaneous tumoral and/or inflammatory form of the disease.